KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block. (January 2022)

• Record Type: Journal Article
• Authors: Garcia-Robledo, Juan Esteban; Rosell, Rafael; Ruíz-Patiño, Alejandro; Sotelo, Carolina; Arrieta, Oscar; Zatarain-Barrón, Lucia; Ordoñez, Camila; Jaller, Elvira; Rojas, Leonardo; Russo, Alessandro; de Miguel-Pérez, Diego; Rolfo, Christian; Cardona, Andrés F.
• Is Part Of: Therapeutic advances in respiratory disease. Volume 16(2022)
• Publication Date: 2022-01
• Subjects: biomarker -- directed therapy -- genomic profiling -- KRAS -- MET -- non-small-cell lung cancer -- resistance -- targeted therapy -- tumor genomics; Respiratory organs -- Diseases -- Periodicals; Respiratory agents -- Periodicals; Pulmonary pharmacology -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System Agents -- therapeutic use -- Periodicals; Respiratory Tract Diseases -- drug therapy -- Periodicals; Lung Diseases -- drug therapy -- Periodicals; Appareil respiratoire -- Maladies -- Traitement -- Périodiques; Agents respiratoires -- Périodiques; Pharmacologie pulmonaire -- Périodiques; 616.2005
• DOI: 10.1177/17534666211066064
• Languages: English
• ISSNs: 1753-4658

Abstract

Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor's molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice.